Result of Secondary Placing in Applied Nutrition
Panmure Liberum Limited
11 September 2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR ACQUIRE SECURITIES IN IN ANY JURISDICTION.
This announcement contains inside information as stipulated under the Market Abuse Regulation no 596/2014 (incorporated into UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019). Upon the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain.
11 September 2026
Result of secondary placing of ordinary shares in Applied Nutrition plc ("Applied Nutrition" or the "Company")
Further to the announcement on 10 September 2026, Thomas Ryder and Steven Granite (together, the "Selling Shareholders") announce that they have agreed to sell 7,000,000 ordinary shares of Applied Nutrition (the "Placing Shares"), at a price of 275 pence per Placing Share, which represents approximately 2.80% of Applied Nutrition's issued share capital (the "Placing").
This represents the first sale of shares for the Selling Shareholders since the Company's IPO in October 2024 and diversifies their asset base. Following completion of the Placing, Thomas Ryder remains Applied Nutrition's largest shareholder with a resultant holding of 81,162,494 ordinary shares in the Company, representing 32.46% of Applied Nutrition's issued share capital.
The Selling Shareholders have undertaken not to dispose of any further ordinary shares in Applied Nutrition for a period of 180 days following completion of the Placing, subject to certain exceptions and waiver by Panmure Liberum.
The trade date for the Placing will be 11 September 2026 and settlement is expected to occur on 15 September 2026.
Panmure Liberum Limited ("Panmure Liberum") acted as sole bookrunner for the Selling Shareholders in connection with the Placing.
The Company is not party to the Placing and will not receive any proceeds from the Placing.
Enquiries:
|
Panmure Liberum (Sole Bookrunner) Investment Banking: Bidhi Bhoma, Edward Thomas ECM: Jamie Loughborough, Rauf Munir |
+44 20 3100 2000 |
IMPORTANT NOTICE
Members of the public are not eligible to take part in the Placing. This announcement is for information purposes only and is directed only at: (a) persons in member states of the European Economic Area ("EEA") who are qualified investors within the meaning of Article 2(e) of regulation (EU) 2017/1129 (the "Prospectus Regulation") ("Qualified Investors") and (b) in the United Kingdom, persons who are (i) "Qualified Investors" within the meaning of paragraph 15 of schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 (the "POATR") and who have (ii) professional experience in matters relating to investments who fall within the definition of "Investment Professionals" in Article 19(5) of the Financial Services And Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the Order or (c) persons to whom it may otherwise be lawful to communicate it (each a "Relevant Person"). No other person should act or rely on this announcement and persons distributing this announcement must satisfy themselves that it is lawful to do so. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. The announcement does not itself constitute an offer for sale of any securities.
This announcement is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia, Japan, South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of the Placing Shares or possession or distribution of this announcement in any jurisdiction where action for that purpose is required.
Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or purchase whatsoever in any jurisdiction and shall not constitute or form part of an offer to sell or the solicitation of an offer to buy any securities in the United States or in any other jurisdiction.
The Placing Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold, or transferred, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States. No public offering of the Placing Shares will be made in the United States or elsewhere.
No prospectus or offering document has been or will be prepared in connection with the Placing. Any investment decision in connection with the Placing must be made on the basis of all publicly available information relating to Applied Nutrition's shares. Such information has not been independently verified. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.
In connection with the Placing, Panmure Liberum or any of its respective affiliates may take up a portion of the Placing Shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for its own accounts such Placing Shares and other securities of Applied Nutrition or related investments in connection with the Placing or otherwise. Accordingly, references to the Placing Shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by Panmure Liberum and any of their respective affiliates acting as investors for their own accounts. Panmure Liberum does not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.
This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in Applied Nutrition or its shares.
Panmure Liberum is authorised and regulated by the Financial Conduct Authority. Panmure Liberum is acting for the Selling Shareholders only in connection with the Placing and no one else, and will not be responsible to anyone other than the Selling Shareholders for providing the protections offered to clients of Panmure Liberum nor for providing advice in relation to the Placing Shares or the Placing, the contents of this announcement or any transaction, arrangement or other matter referred to in this announcement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.